Current Health News Update: Surge in Bavarian Nordic Shares, Cholera Deaths in Sudan, and Mpox Spread

This health news update highlights a surge in Bavarian Nordic shares due to the mpox vaccine, 300 cholera deaths in Sudan linked to civil war, Sweden's first mpox case, Bavarian Nordic's EU approval bid, and more. The WHO declared mpox a global health emergency again, with cases spread reported in Europe and Pakistan.

Bavarian Nordic's shares saw a significant rally this week, with a 50% increase linked to the growing concern over the mpox virus outbreak. The Danish biotech firm's market success is a direct result of being one of the few companies with an mpox vaccine.

The World Health Organization reported more than 300 fatalities in Sudan due to cholera amid a worsening humanitarian crisis from the ongoing civil war. WHO official Margaret Harris highlighted a spike in infections including cholera, dengue fever, and meningitis in the region.

In a landmark case, Sweden confirmed its first mpox infection, marking the first instance of the virus outside Africa. This comes shortly after the WHO declared the disease a global public health emergency for the second time in two years. The infected individual contracted the virus while in Africa.

Danish biotech Bavarian Nordic has moved to extend its mpox and smallpox vaccine to adolescents, submitting data to the European Union's drug regulator for approval. Adolescents are particularly vulnerable to mpox, which has been declared a global emergency.

(With inputs from agencies.)